Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group
Philipp Karschnia,Jacob S Young,Antonio Dono,Levin Häni,Tommaso Sciortino,Francesco Bruno,Stephanie T Juenger,Nico Teske,Ramin A Morshed,Alexander F Haddad,Yalan Zhang,Sophia Stoecklein,Michael Weller,Michael A Vogelbaum,Juergen Beck,Nitin Tandon,Shawn Hervey-Jumper,Annette M Molinaro,Roberta Rudà,Lorenzo Bello,Oliver Schnell,Yoshua Esquenazi,Maximilian I Ruge,Stefan J Grau,Mitchel S Berger,Susan M Chang,Martin van den Bent,Joerg-Christian Tonn
DOI: https://doi.org/10.1093/neuonc/noac193
2022-08-12
Neuro-Oncology
Abstract:Abstract Background Terminology to describe extent of resection in glioblastoma is inconsistent across clinical trials. A surgical classification system was previously proposed based upon residual contrast-enhancing (CE) tumor. We aimed to (1) explore the prognostic utility of the classification system and (2) define how much removed non-CE tumor translates into a survival benefit. Methods The international RANO resect group retrospectively searched previously compiled databases from 7 neuro-oncological centers in the USA and Europe for patients with newly diagnosed glioblastoma per WHO 2021 classification. Clinical and volumetric information from pre- and postoperative MRI were collected. Results We collected 1,008 patients with newly diagnosed IDHwt glioblastoma. 744 IDHwt glioblastomas were treated with radiochemotherapy per EORTC-26981/22981 (TMZ/RT→TMZ) following surgery. Among these homogenously treated patients, lower absolute residual tumor volumes (in cm3) were favorably associated with outcome: patients with “maximal CE resection” (class 2) had superior outcome compared to patients with “submaximal CE resection” (class 3) or “biopsy” (class 4). Extensive resection of non-CE tumor (≤5 cm3 residual non-CE tumor) was associated with better survival among patients with complete CE resection, thus defining class 1 (“supramaximal CE resection”). The prognostic value of the resection classes was retained on multivariate analysis when adjusting for molecular and clinical markers. Conclusions The proposed “RANO categories for extent of resection in glioblastoma” are highly prognostic and may serve for stratification within clinical trials. Removal of non-CE tumor beyond the CE tumor borders may translate into additional survival benefit, providing a rationale to explicitly denominate such “supramaximal CE resection.”
oncology,clinical neurology